Gilead ’s Investigational Antiviral Veklury (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 28, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) enabling use of the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials